Free Newsletter
FDA scientist Torti moves to the helm
And the acting FDA commissioner will be... Frank Torti (photo), who's now chief scientist and principal deputy commissioner. Torti will take the reins at FDA on Inauguration Day, fast on the heels of current commish Andrew von Eschenbach, and will serve until a permanent leader is named.
As you know, Torti joined FDA last year as its first chief scientist. He had been a cancer researcher, serving as director of the Comprehensive Cancer Center of Wake Forest University. If you've been following the who'll-be-the-next-FDA-chief speculation, you know that some pharma observers were canny enough to suggest Torti as a top candidate to lead the agency, at least in the interim. And as those same observers pointed out, the interim job is just one step away from the permanent one.
Given the sad state of science at the FDA, putting a scientist in charge might be just the ticket. You'll recall that the agency's own Science Board gave it a scathing review last fall, saying that FDA is woefully behind the times, lacking talent, funding and technology. Since then, the agency has gone on a hiring spree and Congress has upped its funding (though probably not enough).
But just last week, agency scientists raised new concerns about its operations; they begged President-elect Obama to appoint an FDA chief who would stay out of their business. Management had been coercing them to spin their data, they said, and they want that to stop--and they want the agency culture to change so that they can act with integrity without fear of smackdown. We'll have to wait and see how Torti might deal with that one.
- see In Vivo's blog post
- check out the Wall Street Journal Health Blog article
Related Articles:
Frank Torti, future FDA chief?
FDA chief to step down
Who will take over at the FDA, HHS?
December FDA news in review
Comments
Hey. We are made to persist. That's how we find out who we are.
I am from Botswana and too bad know English, give true I wrote the following sentence: "Myspace video check out exclusive clips more.Also see map, employee and sales information, plus products and services offered."
With best wishes :), Helaine.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: